198 related articles for article (PubMed ID: 32162349)
1. Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study.
Nakano E; Takahashi A; Namikawa K; Muto Y; Jinnai S; Kage Y; Mizuta H; Tsutsumida A; Yamazaki N
J Dermatol; 2020 Jun; 47(6):622-628. PubMed ID: 32162349
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
3. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
5. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
[TBL] [Abstract][Full Text] [Related]
6. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.
Chan L; Hwang SJE; Byth K; Kyaw M; Carlino MS; Chou S; Fernandez-Penas P
J Am Acad Dermatol; 2020 Feb; 82(2):311-316. PubMed ID: 31233857
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
8. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.
Minniti G; Anzellini D; Reverberi C; Cappellini GCA; Marchetti L; Bianciardi F; Bozzao A; Osti M; Gentile PC; Esposito V
J Immunother Cancer; 2019 Apr; 7(1):102. PubMed ID: 30975225
[TBL] [Abstract][Full Text] [Related]
11. Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy.
Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
Eur J Cancer; 2019 Jul; 115():13-16. PubMed ID: 31082687
[No Abstract] [Full Text] [Related]
12. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
13. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients.
Nardin C; Jeand'heur A; Bouiller K; Valnet-Rabier MB; Dresco F; Castagna J; Mareschal A; Carlet C; Nerich V; Limat S; Puzenat E; Aubin F
J Am Acad Dermatol; 2020 Mar; 82(3):770-772. PubMed ID: 31734192
[No Abstract] [Full Text] [Related]
15. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
Ascierto PA; Long GV; Robert C; Brady B; Dutriaux C; Di Giacomo AM; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Ny L; Arance A; Svane IM; Schadendorf D; Gogas H; Saci A; Jiang J; Rizzo J; Atkinson V
JAMA Oncol; 2019 Feb; 5(2):187-194. PubMed ID: 30422243
[TBL] [Abstract][Full Text] [Related]
17. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
19. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study.
Nakamura Y; Tanaka R; Asami Y; Teramoto Y; Imamura T; Sato S; Maruyama H; Fujisawa Y; Matsuya T; Fujimoto M; Yamamoto A
J Dermatol; 2017 Feb; 44(2):117-122. PubMed ID: 27510892
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
